Palihapitiya SPAC said to be in talks with ProKidney
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
[NEW YORK] A blank-check firm started by serial dealmaker Chamath Palihapitiya and Suvretta Capital is in merger talks with medical technology company ProKidney LLC, according to people with knowledge of the matter.
The combined company would be valued at more than US$1 billion in a transaction, the people said, asking not to be identified discussing private information. An announcement could come as soon as next week, the people said.
ProKidney and the special purpose acquisition company, Social Capital Suvretta Holdings Corp. III, haven't reached a final agreement and it's possible talks could end without one, they added.
Representatives for ProKidney and the SPAC didn't immediately respond to requests for comment.
ProKidney is developing a technology that restores kidney function by using the patient's own cells, according to its website. The company was started by a group of investors led by Pablo Legorreta, the founder and chief executive officer of Royalty Pharma.
Winston-Salem, North Carolina-based ProKidney acquired InRegen and its affiliate Twin City Bio in 2019 in a US$62 million transaction, according to a statement at the time.
Navigate Asia in
a new global order
Get the insights delivered to your inbox.
The partnership between Palihapitiya and Suvretta Capital has so far resulted in four SPACs that have each raised US$250 million. Each SPAC is targeting a subsector within biotechnology including neurology, oncology, organs and immunology.
BLOOMBERG
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
